Literature DB >> 30946869

Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.

Hiroki Akiyama1, Yoshihiro Umezawa1, Shinya Ishida1, Keigo Okada1, Ayako Nogami2, Osamu Miura3.   

Abstract

FLT3-ITD and FLT3-TKD are the most frequent mutations in acute myeloid leukemia (AML) with the former associated with a poor prognosis. Here we show that inhibition of the deubiquitinase USP9X by its inhibitor WP1130 or EOAI3402143 (G9) induces apoptosis preferentially in cells transformed by these mutant kinases, including FLT3-ITD-positive AML cell line MV4-11 and primary AML cells. Mechanistically, WP1130 induced aggresomal translocation of the mutant kinases, particularly FLT3-ITD in its activated and autophosphorylated conformation, to block the downstream signaling events, which was aggravated by knock down of USP9X. Moreover, USP9X physically associated with FLT3-ITD to inhibit its K63-linked polyubiquitination, while FLT3-ITD induced tyrosine phosphorylation and degradation of USP9X through the ubiquitin/proteasome pathway. WP1130 or G9 also induced oxidative stress to stimulate stress-related MAP kinase pathways and DNA damage responses to activate in cooperation with inhibition of FLT3-ITD signaling the intrinsic mitochondria-mediated apoptotic pathway, which was synergistically enhanced by BH3 mimetics and prevented by overexpression of Bcl-xL or Mcl-1. Thus, USP9X represents a promising target for novel therapies against therapy-resistant FLT3-ITD-positive AML.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BH3 mimetics; Deubiquitinase; EOAI3402143; Mcl-1; WP1130

Year:  2019        PMID: 30946869     DOI: 10.1016/j.canlet.2019.03.046

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

Review 1.  Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.

Authors:  Xiaonan Zhang; Stig Linder; Martina Bazzaro
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

Review 2.  Acute Myeloid Leukemia-Related Proteins Modified by Ubiquitin and Ubiquitin-like Proteins.

Authors:  Sang-Soo Park; Kwang-Hyun Baek
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

Review 3.  Role of K63-linked ubiquitination in cancer.

Authors:  Liangzi Cao; Xiaofang Liu; Bowen Zheng; Chengzhong Xing; Jingwei Liu
Journal:  Cell Death Discov       Date:  2022-10-06

Review 4.  Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.

Authors:  Ainsley Mike Antao; Apoorvi Tyagi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

5.  FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.

Authors:  Daisuke Watanabe; Ayako Nogami; Keigo Okada; Hiroki Akiyama; Yoshihiro Umezawa; Osamu Miura
Journal:  Cancers (Basel)       Date:  2019-11-20       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.